Create your own free news widgets.

As the European Food Safety Authority (EFSA) publishes its assessment on many of the health claims * made by food products, Which? chief policy adviser, Sue Davies, says: 'A huge number of food products claim to have health benefits, but finally we are separating the wheat from the chaff. Incredibly, only a third of health claims looked at by EFSA could be backed up.

There is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products, according to new research published ...

Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition.

NEW YORK (Reuters Health) - Despite earlier health agency warnings, there is no strong evidence that the anti-smoking drug Chantix raises the risk of suicidal thoughts or depression compared to other stop-smoking products, researchers reported Thursday in the British Medical Journal.

Ramon Allones Gigantes is a newly added product on GoCubans' list of Cuban cigars. Customers can now buy two of the brand's products as Ramon Specially Selected are also available for them. ...

Solocigars.com has news for the customers who are not satisfied by the products they purchase online. Should there be someone who does not find the habanos they bought as satisfying as they expected t...

October 8, 2009 9:00AM - 3:00PM Troutman Sanders Washington D.C. Office 401 9th Street NW Suite 1000 Washington D.C. 20004 The Troutman Sanders LLP Tobacco Team is hosting a seminar regarding the recent legislation giving the Food and Drug Administration authority to regulate tobacco products. Our panel of experts will focus on the key provisions and how they will impact your business. Continental Breakfast and Lunch Provided Cocktail Reception to Follow TOPICS WILL INCLUDE * History of the Legislation * What Proponents of the Legislation Will Seek to Accomplish * Implementation Dates * Testing Requirements * Good Manufacturing Practice Requirements * Advertising and Marketing Restrictions * Unique Issues Pertaining to Electronic Cigarettes * Tobacco Harm Reduction * Interplay Between State Regulators and the FDA Legislation * Who Will Pay for the New Regulatory Infrastructure? . . . Stuart L. Craig, Jr., Director-Sales, CSols, Inc. Everett W. Gee III, VP Legal Affairs

About half of the millions of dollars in fees that will pay for the Food and Drug Administration's regulation of tobacco products will come from Henrico County-based Altria Group Inc. The FDA this week started collecting fees from the nation's tobacco companies to fund the agency's newly created Center for Tobacco Products. The user fees, which will be collected quarterly, are based on each company's share of the U.S. tobacco market. The FDA will collect about $23 million for fiscal 2009. That will rise to $235 million in 2010 and grow to $712 million by 2019. The agency did not disclose the assessments for specific companies, but a spokesman for Altria confirmed reports that the company is responsible for about 50 percent of the total fees. Altria owns Philip Morris USA, the leading cigarette maker with about half of the U.S. market.

There is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products, according to new research published on BMJ.com today.

Blue Cross Blue Shield of Michigan announced a new Medicare Advantage PPO product that for many Michigan seniors provides benefits at lower premiums than Original Medicare coupled with Part D drug plans and supplementary coverage.